Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Gains from Investment Securities (2018 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Gains from Investment Securities for 10 consecutive years, with $1603.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gains from Investment Securities changed N/A year-over-year to $1603.0, compared with a TTM value of $339799.0 through Sep 2025, up 196.13%, and an annual FY2024 reading of $4519.0, down 96.06% over the prior year.
  • Gains from Investment Securities was $1603.0 for Q3 2025 at Kiora Pharmaceuticals, down from $219061.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $337515.0 in Q3 2022 and bottomed at -$570203.0 in Q1 2021.
  • Average Gains from Investment Securities over 5 years is $45146.5, with a median of $85610.0 recorded in 2022.
  • Peak annual rise in Gains from Investment Securities hit 2974.53% in 2021, while the deepest fall reached 853.59% in 2021.
  • Year by year, Gains from Investment Securities stood at $12952.0 in 2021, then surged by 2505.89% to $337515.0 in 2022, then tumbled by 66.0% to $114747.0 in 2023, then plummeted by 96.06% to $4519.0 in 2024, then crashed by 64.53% to $1603.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for KPRX at $1603.0 in Q3 2025, $219061.0 in Q2 2025, and $114616.0 in Q1 2025.